Atonco, Arronax’s bud is a young radiopharmaceutical startup in the Nantes ecosystem that is developing innovative radiopharmaceuticals using astatine-211, an alpha particle-emitting radionuclide for the treatment of cancer, to the clinical stage. Founded in 2019 and built with an experienced and passionate team, Atonco holds licenses and patents for the use of innovative antibodies and proprietary radiolabeling technologies. The Atonco team aims to offer patients an innovative therapy that aims to destroy the last cancer cells of residual disease left after conventional cancer treatments, including radiotherapy, chemotherapy and immunotherapy.